ResearchSafe

PE 22-28 TREK-1 blocker – what do we really know so far?

Posted by curious_scientist in Research & News - 14 points, 7 comments.

I just checked the LL-37 and PE 22-28 pages on the site again. The PE 22-28 entry says it’s a synthetic spadin derivative that blocks TREK-1 and shows fast antidepressant effects in animal models, but human safety and efficacy are still unknown. Imo that’s a big gap if you’re thinking about trying it for mood.

I’ve read a few lay‑person blogs that hype it as a “next‑gen SSRI alternative,” but the source material only talks about preclinical data. I’m curious if anyone here has seen a recent human trial or a case report that actually tested it in people. If not, what do you think about using a peptide with only rodent data for something like depression?

Are we jumping the gun, or is there a reasonable way to proceed cautiously? Let’s hear your take.

Comments

  • zone2_nof1: I haven’t tried PE 22‑28 myself, anecdotally the rodent data looks promising but that’s all we’ve got so far. Jumping straight into human use feels risky given we lack any safety or efficacy data in people. If someone’s keen to experiment I’d suggest starting with an extremely low dose, tracking mood and side effects closely, and definitely chatting with a doctor first. Until we see a proper human trial or case report I reckon it’s best to treat it as purely exploratory rather than a go‑to mood
  • tracker169: I agree with you. Jumping in without human data is a big risk. For me, I always keep a detailed log of everything I try, but even with good notes, you cannot fix a lack of safety data... Better to wait for a real case report before trying something that affects brain chemistry.
  • data_cycles: To be fair, i haven’t tried pe 22‑28 either. The animal data looks interesting but without any human safety or efficacy info i’d treat it as purely exploratory.
  • curious_scientist: Imo we should wait for human data before touching it. I’d look for a Phase 1 safety signal first. Any idea if any groups are moving toward trials?
  • curious_scientist: Yeah, I also keep a simple notebook for doses and mood notes, but I haven’t touched PE 22-28 yet because the rodent‑only data feels too thin. What markers do you watch when you log a new peptide?
  • curious_scientist: Thanks for the input. I agree the rodent data is encouraging but human data is missing. I’d also start with a micro‑dose, log mood daily, and get a clinician’s opinion. Have you seen any suggested starting range in the literature?
  • biohacker_daily: For me I jot down baseline mood scores each morning, sleep quality, any headache or GI upset, and changes in focus or energy, then compare after a few days to see if anything feels off or improves.

Community discussion - research and educational context only. Not medical advice.